시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 급성 편두통 치료 시장 보고서(2025년)
Acute Migraine Treatment Global Market Report 2025
상품코드 : 1825594
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,516,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,419,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,322,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

급성 편두통 치료 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 CAGR 11.1%로 44억 1,000만 달러로 성장합니다. 편두통 유병률 증가, 편두통 연구에 대한 투자 증가, 비침습적 치료 옵션에 대한 수요 증가, 즉각적인 완화 옵션에 대한 수요 증가, 환자 중심의 의약품 개발에 대한 중요성 증가가 예측 기간 중 성장을 촉진할 것으로 예측됩니다. 예측 기간의 주요 동향으로는 기술 발전, 신경조절 기기 채택, 맞춤형 의료, 원격의료, 진단 툴 등을 꼽을 수 있습니다.

향후 5년간 11.1%의 성장률 전망은 지난번 전망치보다 0.2% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세로 인해 아일랜드와 덴마크에서 조달하는 칼시토닌 유전자 관련 펩티드(CGRP) 길항제 및 신경차단제 비용이 상승하고 편두통 환자의 획기적인 치료법에 대한 접근이 제한되어 미국 신경과 시장의 가격 경쟁력을 떨어뜨릴 수 있습니다. 또한 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

업무 압박 증가는 급성 편두통 치료 시장의 향후 성장을 촉진할 것으로 예측됩니다. 직무스트레스는 직무상의 요구나 과업으로 인해 직원이 겪는 정신적, 정서적, 신체적 부담을 말합니다. 업무 압박을 증가시키는 요인으로는 촉박한 납기, 자원 및 지원 부족, 일과 삶의 불균형, 직무 역할의 불명확성, 인간관계의 충돌, 조직의 변화 등을 꼽을 수 있습니다. 업무 스트레스 증가와 관련된 급성 편두통 치료는 특히 가혹한 작업 환경에서 스트레스로 인해 유발되거나 악화될 수 있는 편두통 증상의 관리에 초점을 맞추었습니다. 예를 들어 2022년 10월 미국 심리학자 단체인 미국심리학회는 직장내 스트레스가 여전히 중요한 문제이며, 직원의 77%가 지난 한 달 동안 업무 관련 스트레스를 경험했다고 보고했습니다. 또한 57%의 직원이 정서적 피로(31%)와 같은 부정적인 영향을 받는다고 답했으며, 이는 직장내 소진과 관련이 있는 것으로 나타났습니다. 따라서 업무 압박 증가는 급성 편두통 치료 시장의 성장을 가속하고 있습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장의 거시경제 시나리오 : 금리·인플레이션·지정학·무역 전쟁·관세·Covid와 회복이 시장에 미치는 영향을 포함한다

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계 시장 : 경쟁 벤치마킹·대시보드

제33장 주요 기업인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력의 높은 국가·부문과 전략

제36장 부록

KSA
영문 목차

영문목차

Acute migraine treatments involve therapies aimed at providing immediate relief from migraine attacks by addressing symptoms such as intense headaches, nausea, and heightened sensitivity to light and sound. These treatments are designed to reduce the severity and duration of migraines, improving patient comfort and functionality during episodes.

The primary types of drugs used for acute migraine treatment include triptans, calcitonin gene-related peptide (CGRP) antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), beta-adrenergic blockers, ergot alkaloids, and others. Triptans are medications that specifically target serotonin 1B and 1D receptors, leading to vasoconstriction and reducing the release of inflammatory substances. They are considered specific treatments for migraines and are commonly used for acute relief. These medications can be administered orally, through injection, or by other methods and are available through various distribution channels, including hospital pharmacies, retail pharmacies, drug stores, and online platforms.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The acute migraine treatments market research report is one of a series of new reports from The Business Research Company that provides acute migraine treatments market statistics, including acute migraine treatments industry global market size, regional shares, competitors with an acute migraine treatments market share, detailed acute migraine treatments market segments, market trends, and opportunities, and any further data you may need to thrive in the acute migraine treatments industry. This acute migraine treatments research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acute migraine treatment market size has grown rapidly in recent years. It will grow from $2.6 billion in 2024 to $2.9 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to the increasing prevalence of migraine, growth of specialty clinics, increasing funding for migraine research, growth in clinical trials, and increasing use of preventive medications.

The acute migraine treatment market size is expected to see rapid growth in the next few years. It will grow to $4.41 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to the increasing prevalence of migraine, growing investment in migraine research, rising demand for non-invasive treatment options, rising demand for quick-acting relief options, and growing emphasis on patient-centric drug development. Major trends in the forecast period include technological advancements, the adoption of neuromodulation devices, personalized medicine, telemedicine, and diagnostic tools.

The forecast of 11.1% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The U.S. neurology market may see reduced affordability as tariffs increase the cost of Calcitonin gene-related peptide(CGRP) inhibitors and nerve block supplies sourced from Ireland and Denmark, limiting access to breakthrough therapies for migraine sufferers. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing work pressure is anticipated to drive the growth of the acute migraine treatment market moving forward. Work pressure refers to the mental, emotional, and physical strain that employees experience due to the demands and challenges of their job roles. Contributing factors to the increase in work pressure include tight deadlines, insufficient resources and support, poor work-life balance, unclear job roles, interpersonal conflicts, and organizational changes. Acute migraine treatment for heightened work pressure focuses on managing migraine symptoms that may be triggered or worsened by stress, particularly in demanding work environments. For example, in October 2022, the American Psychological Association, a US-based association of psychologists, reported that workplace stress remains a significant issue, with 77% of employees experiencing work-related stress in the past month. Furthermore, 57% of employees mentioned suffering negative effects, such as emotional exhaustion (31%), often associated with workplace burnout. Hence, the increasing work pressure is fueling the growth of the acute migraine treatment market.

Leading companies in the acute migraine treatment market are focused on developing innovative solutions, such as nasal sprays, to improve the effectiveness and convenience of migraine relief. Migraine nasal sprays administer medication through the nasal passages, offering the benefit of rapid absorption and quicker relief compared to oral medications. For example, in March 2023, Pfizer Inc., a US-based biotechnology company, introduced ZAVZPRET (zavegepant) Migraine Nasal Spray, approved by the FDA. This nasal spray uses zavegepant, a CGRP receptor antagonist, to block the calcitonin gene-related peptide (CGRP) pathway, providing swift and targeted relief from migraines. ZAVZPRET's fast-acting formulation offers relief within 15 minutes, making it a convenient choice for those seeking quick relief from severe migraine symptoms.

In October 2022, Pfizer Inc. acquired Biohaven Pharmaceutical Holding Company Ltd. for $11.6 billion. This acquisition aims to enhance Pfizer's position in the neurology and pain management sectors by integrating Biohaven's innovative migraine treatments and other neurological therapies. Biohaven Pharmaceutical Holding Company Ltd. specializes in treatments for acute migraines.

Major companies operating in the acute migraine treatment market are Pfizer Inc., Johnson And Johnson, Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Viatris Inc., Allergan plc, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Endo International plc, Supernus Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Upsher-Smith Laboratories LLC, BioDelivery Sciences International Inc., Axsome Therapeutics Inc., Impel NeuroPharma Inc., Currax Pharmaceuticals LLC, Satsuma Pharmaceuticals Inc.

North America was the largest region in the acute migraine treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute migraine treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the acute migraine treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute migraine treatment market consists of revenues earned by entities by providing emergency room (ER) services, headache centers, primary care physicians, and pain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute migraine treatment market also includes sales of acetaminophen, anti-nausea medications, CGRP antagonists, and transcranial magnetic stimulation (TMS) devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Migraine Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute migraine treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for acute migraine treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The acute migraine treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Acute Migraine Treatment Market Characteristics

3. Acute Migraine Treatment Market Trends And Strategies

4. Acute Migraine Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Acute Migraine Treatment Growth Analysis And Strategic Analysis Framework

6. Acute Migraine Treatment Market Segmentation

7. Acute Migraine Treatment Market Regional And Country Analysis

8. Asia-Pacific Acute Migraine Treatment Market

9. China Acute Migraine Treatment Market

10. India Acute Migraine Treatment Market

11. Japan Acute Migraine Treatment Market

12. Australia Acute Migraine Treatment Market

13. Indonesia Acute Migraine Treatment Market

14. South Korea Acute Migraine Treatment Market

15. Western Europe Acute Migraine Treatment Market

16. UK Acute Migraine Treatment Market

17. Germany Acute Migraine Treatment Market

18. France Acute Migraine Treatment Market

19. Italy Acute Migraine Treatment Market

20. Spain Acute Migraine Treatment Market

21. Eastern Europe Acute Migraine Treatment Market

22. Russia Acute Migraine Treatment Market

23. North America Acute Migraine Treatment Market

24. USA Acute Migraine Treatment Market

25. Canada Acute Migraine Treatment Market

26. South America Acute Migraine Treatment Market

27. Brazil Acute Migraine Treatment Market

28. Middle East Acute Migraine Treatment Market

29. Africa Acute Migraine Treatment Market

30. Acute Migraine Treatment Market Competitive Landscape And Company Profiles

31. Acute Migraine Treatment Market Other Major And Innovative Companies

32. Global Acute Migraine Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Migraine Treatment Market

34. Recent Developments In The Acute Migraine Treatment Market

35. Acute Migraine Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기